Compare Amylx Pharmaceuticals Inc (AMLX) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Huntington Bancshares Incorporated — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Huntington Bancshares Incorporated trades at $17.89 (market cap $36.22B). The key difference: Huntington Bancshares Incorporated is far larger — about 18.3× Amylx Pharmaceuticals Inc's market cap, and Huntington Bancshares Incorporated pays a 3.47% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HBAN | |
|---|---|---|
Market Cap | $1.98B | $36.22B |
Sector | Health | Financials |
52-Week High | $18.70 | $19.27 |
52-Week Low | $7.64 | $15.02 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
HBAN trades at $17.87, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.25. Recent Q1 2026 earnings beat expectations with EPS of $0.26, and revenue for 2025 grew to $8.13B. The company maintains a solid net income margin of 25.13% and a P/E ratio of 13.75, indicating reasonable valuation. News highlights include expansion in Texas and a recent dividend payment, supporting positive sentiment.
The outlook for HBAN is positive, with growth driven by strategic acquisitions and organic loan expansion, though risks include integration challenges and competitive pressures in regional banking. Analysts are predominantly bullish, with 49% recommending buy, suggesting potential upside from current levels if earnings targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
